Mandate

Vinge advises Active Biotech on rights offering

February 15, 2018 Capital Markets and Public M&A

Active Biotech AB (publ) issues new shares with pre-emptive rights for the shareholders.

The Vinge team includes Erik Sjöman, Christian Lindhé, Astrid Karlsson and Jack Bengtsson.
 

Related

Vinge has advised Orexo in connection with the divestment of the US rights to Zubsolv

Vinge has advised Orexo in relation to Swedish law in connection with the divestment of the US rights to Zubsolv to Dexcel Pharma USA.
January 14, 2026

Vinge advises Morrow Bank in connection with cross-border merger and list change from Oslo Børs to Nasdaq Stockholm

Vinge has advised Morrow Bank in connection with its reverse cross-border merger, whereby Morrow Bank AB is taking over Morrow Bank ASA. The Norwegian bank was previously listed on the Oslo Stock Exchange which was today transferred to Nasdaq Stockholm. Vinge has previously assisted Morrow Bank in obtaining a Swedish banking licence.
January 12, 2026

Vinge advises Dunlop Aircraft Tyres in connection with its issuance of USD 93 million senior secured bonds

Vinge has advised Dunlop, in connection with its issuance of senior secured bonds in the amount of USD 93 million, under a total framework of USD 120 million.
January 08, 2026